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The  efﬁcacy  of  a single  oral  dose  of  a novel  isoxazoline,  sarolaner  (SimparicaTM, Zoetis),  for  the treat-
ment  and  control  of  ﬂea infestations  on  dogs  was  conﬁrmed  in  ﬁve  laboratory  studies.  The  studies  were
conducted  using  adult  purpose-bred  Beagles  and/or  mixed  breed dogs.  All animals  were  individually
identiﬁed  and  housed,  and  were  allocated  randomly  to treatment  with  either  placebo  or sarolaner  (eight
to  10  per group)  based  on pretreatment  parasite  counts.  Three  studies  used  cat ﬂea  (Ctenocephalides  felis
felis)  strains  recently  isolated  from  the  ﬁeld  from  the  US,  EU,  or Australia;  in  the  fourth  study  a  laboratory
strain  (KS1)  with  documented  tolerance  to  a number  of  insecticides  such  as  ﬁpronil,  imidacloprid,  and
permethrin  was  used. In the ﬁfth  study,  dogs  were  infested  with  dog  ﬂeas,  Ctenocephalides  canis.  Dogs
were  treated  orally  on Day  0 with  a  placebo  or a sarolaner  tablet providing  a minimum  dose  of  2  mg/kg.
Dogs  were  infested  with  approximately  100  unfed,  adult  ﬂeas  prior  to  treatment  and  at weekly  inter-
vals  post-treatment.  Comb  counts  were  conducted  to determine  the  numbers  of viable  ﬂeas  at  24 h  after
treatment  and  after  each  subsequent  infestation.  Efﬁcacy  against  C.  felis  and  C.  canis  was  99.8–100%  from
treatment  through  Day  35.  In all ﬁve  studies,  elimination  of  existing  infestations  was  achieved  within  24  h
after  dosing,  with  only a single  live  C. felis  found  on  one  dog  on Day  1.  Similarly,  control  of  ﬂea challenges
was  achieved  within  24  h after infestation  throughout  the  35  day  study  periods,  with  only  single  live C.
felis found  on two  dogs  on Day  28  in one  study,  and  on  a  single  dog  on  Day  35 in  another  study.  There
were  no adverse  reactions  to treatment  with  sarolaner.  These  studies  conﬁrmed  that  a single oral  dose
of sarolaner  at 2 mg/kg  provided  highly  effective  treatment  of  existing  C.  felis  infestations  and  persistent
control  of  C.  felis on dogs  for  35  days  after  treatment.  Efﬁcacy  equivalent  to that  seen with C. felis was
conﬁrmed  against  C.  canis  and a  known  insecticide-tolerant  strain  of C.  felis.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Flea infestations have been recognized for decades as a common
urden for companion animals and their owners worldwide. Cteno-
ephalides felis felis (cat ﬂea) is considered to be the most common
ctoparasite of companion animals and has a worldwide distribu-
ion (Rust and Dryden, 1997). Ctenocephalides canis (dog ﬂea) has a
∗ Corresponding author.
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/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
similar distribution, host spectrum, and biology to C. felis (Krämer
and Menke, 2001) but is generally less commonly encountered.
They are recognized as a major cause of pruritus in companion
animals, are intermediate hosts for the dog tapeworm, Dipylidium
caninum, and can transmit a number of pathogens including Bar-
tonella henselae (Kwochka, 1987; Foil et al., 1998; Breitschwerdt
and Kordick, 2000; Krämer and Menke, 2001; Breitschwerdt et al,
2010), Bartonella clarridgeae and Bartonella koehlerae (Chomel and
Kasten, 2010), and Rickettsia felis (Horta et al., 2014). Adult ﬂeas are
blood feeders, penetrating the skin with their sucking mouthparts
and injecting salivary antigens as they feed, and when present in
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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arge numbers are capable of causing anemia (Dryden, 1989). Given
he high prevalence and the pathogenic and zoonotic potential of
eas (Beugnet and Franc, 2012), ﬂea control should be a high pri-
rity in wellness programs targeted at maintaining the health of
ogs and cats over their lifetime. Key objectives for ﬂea-control
rograms include rapid speed of kill for existing infestations on
he animal, prevention of re-infestation of the pet with on-going
xposure, and rapid elimination of adult ﬂeas prior to egg produc-
ion (Carlotti and Jacobs, 2000). Successful control and prevention
nhances the human-companion animal bond by preventing these
rritating and debilitating parasites, controlling signs of ﬂea allergy
ermatitis in allergic animals, and helping protect pets and their
wners from exposure to vector-borne pathogens by minimizing
ector exposure.
Control of ﬂeas depends upon chemical parasiticides and
n-animal treatments generally applied as monthly spot-on appli-
ations have been the standard accepted method (Dryden and
ayne, 2004; Rust, 2005). Spot-on treatments include active ingre-
ients from a number of chemical classes, including phenyl
yrazoles, ﬁpronil; neonicotinoids, imidacloprid; the pyrethroids,
ermethrin and phenothrin; and selamectin, an avermectin (Rust,
005). There are also products such as the insect growth regula-
ors, lufenuron, pyriproxyfen, and methoprene, that control ﬂeas
y disrupting the development of eggs and larvae. Fleas have devel-
ped resistance to a number of insecticides; pest management
trategies to reduce further development of resistance have been
roposed (Bossard et al., 1998; Ross et al., 1998; Rust, 2005) to
ctively manage the use of these products to attempt to preserve
he effectiveness of these older active ingredients. Newer classes of
ral formulations have been introduced and have gained accep-
ance for their convenience and consistent efﬁcacy as these are
naffected by environmental factors (sun, bathing, swimming, etc.)
nd owner application variation that can impact efﬁcacy of topical
roducts. These oral products include spinosad (for ﬂeas only) and
he recently introduced isoxazoline compounds that provide con-
rol of both ﬂeas and ticks (Robertson-Plouch et al., 2008; Rohdich
t al., 2014; Shoop et al., 2014).
Sarolaner is an isoxazoline ectoparasiticide with insecti-
ide/acaricide activity that has excellent efﬁcacy against ﬂeas on
ogs following oral administration at a minimum dose of 2 mg/kg
McTier et al., 2016). Here we report a series of laboratory studies
onducted to conﬁrm the efﬁcacy of sarolaner (SimparicaTM, Zoetis)
iven as a single oral dose to dogs for the treatment of existing ﬂea
nfestations, and the persistent control of ﬂeas for one month. These
tudies assessed efﬁcacy versus C. felis strains representative of cur-
ent ﬁeld populations from the US, Europe, and Australia, and a
uropean strain of C. canis. Further, efﬁcacy of sarolaner was eval-
ated against a known insecticide resistant strain of C. felis, KS1,
Dryden, 1998; Payne et al., 2001; Bossard et al., 2002; Rust et al.,
002; Dryden et al., 2005, 2008).
. Materials and methods
Five studies were conducted to conﬁrm the efﬁcacy of the pro-
osed minimum label dose of 2 mg  sarolaner/kg against existing
ea infestations and weekly challenges up to 35 days after a sin-
le oral dose. Four studies evaluated C. felis, and in the ﬁfth study
fﬁcacy was conﬁrmed against C. canis (Table 1).
The studies were conducted in accordance with the World Asso-
iation for the Advancement of Veterinary Parasitology (WAAVP)
uidelines for evaluating the efﬁcacy of parasiticides for the treat-
ent, prevention and control of ﬂea and tick infestation on dogs
nd cats (Marchiondo et al., 2013) and complied with Good Clin-
cal Practices (VICH guideline GL9) (EMEA, 2000). Study protocolstology 222 (2016) 18–22 19
were reviewed and approved by the local and/or Zoetis Institutional
Animal Care and Use Committee.
2.1. Animals
The studies used purpose bred Beagle and/or mixed breed dogs
of both sexes, ranging in age from 9 to 96 months and weighing
from 6.0 to 26.0 kg (Table 1). All dogs had demonstrated good ﬂea
retention prior to treatment, were in good health at enrolment, and
had not been treated with an ectoparasiticide for at least 60 days.
Dogs were individually identiﬁed and housed in enclosures that
conformed to accepted animal welfare guidelines and ensured no
direct contact between dogs. Dogs were fed an appropriate main-
tenance ration of a commercial dry canine feed for the duration of
the study. Water was available ad libitum.
2.2. Experimental design and methods
Dogs were acclimated to the study conditions for at least 14 days
prior to treatment. The dogs were observed for general health
at least once daily throughout the studies by personnel qualiﬁed
through training and experience. A physical exam was  performed
on each dog by a veterinarian to determine health and suitabil-
ity prior to inclusion in the study. For infestations, dogs were held
and approximately 100 ﬂeas were applied directly to the dogs
and allowed to disperse into the hair coat. Flea counts were per-
formed by personnel trained in the standard procedures in use
at the test facilities. Protective gloves and clothing were changed
between dogs and personnel conducting parasite or other obser-
vations were masked to treatment assignments. The dogs were
thoroughly combed to remove ﬂeas for counting. Fleas able to stand
upright and/or move in a coordinated manner were considered live.
Commercial ﬁne-toothed ﬂea combs were used. Dogs were sys-
tematically combed using repeated strokes while standing, starting
from the head and proceeding caudally along the dorsum. The dog
was then placed in lateral recumbency, followed by dorsal recum-
bency, for combing of the sides and ventral surfaces. Each animal
was examined for a minimum of 10 min. Any animal on which ﬂeas
were found in the last ﬁve minutes was combed for an additional
ﬁve minutes (one minute in Study 3).
Approximately one week prior to treatment, 20–22 dogs were
infested with ﬂeas. These dogs were then combed to count ﬂeas
24 ± 2 h later. The 16 dogs (20 dogs in study 3) with the highest live
ﬂea counts were selected for inclusion in each study. The dogs were
ranked by ﬂea count and then randomly assigned to either placebo
control or treatment with sarolaner.
Day 0 for each study was the day on which dogs were adminis-
tered study treatment. On Day-1, all dogs were infested with ﬂeas.
On Day 0, the dogs were offered their normal ration of food ∼20 min
prior to dosing (one hour in Study 4). In Studies 1–5, dogs treated
with sarolaner were administered a single or combination of tablets
from strengths of 5, 10, 20 or 40 mg  to achieve the appropriate
dose (as close as possible to 2.0 mg  sarolaner/kg without under dos-
ing). Placebo-control dogs were dosed with similarly sized placebo
tablets. In Study 4, 40 mg  sarolaner tablets were individually shaved
and/or sanded to deliver the minimum dosage of 2.0 mg/kg and
control dogs received a single placebo tablet. To ensure complete
dosing in these laboratory studies, all dogs were hand-pilled. Each
dog was observed for several minutes to make sure the dose was
swallowed and for any adverse events associated with adminis-
tration, and then periodically for up to two  hours for any signs of
emesis. Dogs were observed for general health and any reaction
to treatment approximately 1, 3, and 6 h after treatment on Day 0,
then at least once daily for the remainder of the study.
On Day 1, approximately 24 h after treatment, each dog was
examined and combed to count and remove ﬂeas. Subsequently,
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Table  1
Study locations, age and weight ranges of dogs, and parasite details for ﬁve studies evaluating the efﬁcacy of sarolaner against ﬂeas.
Study Dogs Parasite
# Location Number Age (months) Weight (kg) Species Source and History
1 Arkansas, USA 16 9–66 6.0–14.6 Ctenocephalides felis Lab colony (NC), infusion of ﬁeld ﬂeas (AR) 2 years prior to study
2  Ireland 16 13–69 9.2–7.5 Ctenocephalides felis Lab colony (UK), infusion of ﬁeld ﬂeas (EU) 9 years prior to study
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13  New South Wales,Australia 20 36–96 7.5–26.0 Ctenoc
4  Arkansas, USA 16 20–22 6.8–10.6 Ctenoc
5  Ireland 16 15–85 9.0–15.9 Ctenoc
ll animals were infested with ﬂeas on Days 6, 13, 20, 26 (27 in
tudy 3) and 34. All dogs were examined and combed to count and
emove ﬂeas 24 h after each infestation.
.3. Parasites
Fleas for all studies were obtained from local laboratory colonies
nd with the exception of Study 4 (KS1 strain) these colonies had
ll been infused with additional ﬁeld collected ﬂeas within two
o nine years of the study (Table 1). The KS1 strain of C. felis
as obtained from Kansas State University, Manhattan, KS. This
olony was established in 1990 and has since been maintained as a
losed colony. This colony has some level of resistance or reduced
usceptibility to carbaryl, imidacloprid, ﬁpronil, permethrin, and
yrethrins (Dryden, 1998; Payne et al., 2001; Bossard et al., 2002;
ust et al., 2002; Dryden et al., 2005). This C. felis strain has been
epeatedly evaluated for its susceptibility to various insecticides
nd has been used in several evaluations of ﬂea products (Dryden,
998; Payne et al., 2001; Dryden et al., 2001, 2002, 2005, 2008;
ossard et al., 2002; Rust et al., 2002; Bass et al., 2004a,b).
.4. Data analysis
The individual dog was the experimental unit and the primary
ndpoint was the live ﬂea count. Flea counts were transformed
y the loge (count + 1) transformation prior to analysis in order
o stabilize the variance and normalize the data. Using the PROC
IXED procedure (SAS 9.2, Cary NC), transformed counts were ana-
yzed using a mixed linear model for repeated measures. The model
ncluded the ﬁxed effect of treatment, day of study, and the inter-
ction between treatment and day of study. The random effects
ncluded block, the interaction between block and treatment, and
rror. Testing was two-sided at the signiﬁcance level =0.05. Per-
ent efﬁcacy relative to the control group was calculated as follows:
Efﬁcacy = (Mean Control - Mean Treated)
Mean Control
× 100
. Results
.1. Efﬁcacy
Across all ﬁve studies treatment with a single oral dose of
arolaner was highly effective in controlling existing infestations
nd subsequent weekly re-infestations of C. felis and C. canis on
ogs for 35 days (Table 2).
In Study 1, placebo-treated dogs maintained C. felis infestations
hroughout the study with post-treatment geometric mean counts
anging from 62.7 to 96.3C. felis/dog. Individual dog counts ranged
rom 11 to 100, and at least six of eight dogs had >70C. felis on each
ount day. No live C. felis were recovered from sarolaner-treated
ogs at any post-treatment count. Thus efﬁcacy was  100% from Day
 through Day 35 after a single oral dose. Live C. felis counts wereides felis Lab colony (NSW), infusion of ﬁeld ﬂeas (NSW) 2 years prior to study
ides felis KS1 strain, KS, maintained as a closed colony since 1990
ides canis Lab colony established with ﬁeld ﬂeas 4 years prior to study
signiﬁcantly lower for the sarolaner-treated dogs than placebo at
all time-points (P < 0.0001).
In Study 2, dogs in the placebo group maintained C. felis infes-
tations throughout the study with post-treatment geometric mean
counts ranging from 62.4 to 85.8C. felis/dog. Individual dog counts
ranged from 16 to 99, and at least six of eight dogs had >55 C. felis
on each count day. No live C. felis were recovered from sarolaner-
treated dogs at any post-treatment count up to Day 28; a single live
C. felis was found on one dog on Day 35. Thus efﬁcacy was  100% from
Day 1 through Day 28, and 99.9% on Day 35 after a single oral dose.
Live C. felis counts were signiﬁcantly lower for the sarolaner-treated
dogs than placebo at all time-points (P < 0.0001).
In Study 3, placebo-treated dogs had post-treatment geometric
mean counts ranging from 59.2 to 83.3C. felis/dog. Individual dog
counts ranged from 19 to 106, and at least seven of 10 dogs had
>60C. felis on each count day. No live C. felis were recovered from
sarolaner-treated dogs on Days 7, 14, 21 and 35. Single C. felis were
found on one dog on Day 1, and on two  dogs on Day 28. Thus, after a
single oral dose, efﬁcacy was 99.9% on Day 1, 99.8% on Day 28, and
100% on all other count days. Live C. felis counts were signiﬁcantly
lower for the sarolaner-treated dogs than placebo at all time-points
(P < 0.0001).
In Study 4, placebo-treated dogs maintained good C. felis infes-
tations throughout the study with post-treatment geometric mean
counts ranging from 69.0 to 94.4C. felis/dog. Individual dog counts
ranged from 56 to 101, and at least six of eight dogs had >70C. felis
on each count day. No live C. felis were recovered from sarolaner-
treated dogs at any time post-treatment. Thus efﬁcacy was 100%
from Day 1 day through Day 35 after a single oral dose. Live C. felis
counts were signiﬁcantly lower for the sarolaner-treated dogs than
placebo at all time-points (P < 0.0001).
In Study 5, dogs in the placebo group maintained C. canis infes-
tations throughout the study with post-treatment geometric mean
counts ranging from 70.9 to 95.4C. canis/dog. Individual dog counts
ranged from 47 to 102, and at least six of eight dogs had >65C. canis
on each count day. No live C. canis were recovered from sarolaner-
treated dogs at any post-treatment count through Day 35. Thus
efﬁcacy was 100% from Day 1 through Day 35 after a single oral
dose. Live C. canis counts were signiﬁcantly lower for the sarolaner-
treated dogs than placebo at all time-points (P < 0.0001).
3.2. Dose acceptance
All animals were dosed completely; no tablets were expelled
and no evidence of emesis of tablets was seen in any study. Two
dogs in one study were noted to either gag or cough following the
administration of water immediately following dosing.3.3. Health observations
No adverse events related to treatment with sarolaner occurred
in any study.
R.H. Six et al. / Veterinary Parasitology 222 (2016) 18–22 21
Table  2
Geometric mean ﬂea counts for placebo dogs and percent efﬁcacy relative to placebo at 24 h after treatment and weekly infestations for dogs treated orally with sarolaner
tablets at 2 mg/kg.
Day Study 1 (C. felis, AR) Study 2 (C. felis, Ireland) Study 3 (C. felis, NSW) Study 4 (C. felis, KS1) Study 5 (C. canis, Ireland)
Placebo Sarolaner Placebo Sarolaner Placebo Sarolaner Placebo Sarolaner Placebo Sarolaner
1 92.3 0.0* (100) 63.9 0.0* (100) 59.2 0.1*(99.9) 69.0 0.0*(100) 74.4 0.0* (100)
7  96.3 0.0* (100) 70.2 0.0* (100) 70.7 0.0* (100) 90.5 0.0* (100) 95.4 0.0* (100)
14  79.5 0.0* (100) 66.5 0.0* (100) 83.3 0.0* (100) 84.9 0.0* (100) 84.3 0.0* (100)
21  71.9 0.0* (100) 62.4 0.0* (100) 82.3 0.0* (100) 94.0 0.0* (100) 85.4 0.0* (100)
28  62.7 0.0* (100) 79.1 0.0* (100) 79.6 0.2* (99.8) 94.4 0.0* (100) 75.8 0.0* (100)
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t35  75.9 0.0* (100) 85.5 0.1* (99.9) 74.9
* Geometric mean counts are signiﬁcantly lower than placebo; P ≤ 0.0001. Percen
. Discussion
Over all ﬁve studies, sarolaner at the minimum oral dose of
 mg/kg was highly effective for the treatment and control of C.
elis and C. canis infestations for 35 days on dogs and there were
o adverse reactions to treatment. Treatment of existing infesta-
ions was achieved within 24 h after dosing with efﬁcacy ≥99.9%
nd only a single live C. felis found on one dog across all ﬁve studies
n Day 1. Similarly, control of post-treatment C. felis and C. canis
hallenges was achieved within 24 h after infestation throughout
he 35 day study periods, with only single live C. felis found on two
ogs on Day 28 in one study, and a single dog on Day 35 in another
tudy. Thus, the persistent efﬁcacy was ≥99.8% within 24 h after
hallenges for 35 days after a single oral dose of sarolaner. Efﬁcacy
f 100% for ﬁve weeks was also achieved against the KS1 strain;
 ﬂea strain with demonstrated reduced susceptibility to many of
he older topical parasiticides used for ﬂea control.
Although C. felis is considered the predominate ﬂea species
nfesting dogs globally, conﬁrmation that sarolaner has similar
xcellent efﬁcacy against C. canis is also clinically important, as this
pecies has been shown to represent a signiﬁcant proportion of the
eas infesting dogs in the United States and Europe (Franc et al.,
998; Durden, et al., 2005; Beck et al., 2006; Gracia et al., 2007).
Orally dosed ﬂea control products need to be absorbed by the
og and the ﬂeas need to feed in order to ingest an effective dose.
hile these dose conﬁrmation studies did not directly address
peed of kill, it is clear that sarolaner was rapidly effective as vir-
ually all ﬂeas in the existing infestations were killed in less than
4 h after treatment. Similarly, for up to ﬁve weeks after the single
reatment, new ﬂea infestations were almost entirely eradicated in
ess than 24 h after infestation. In separate studies, it was conﬁrmed
hat sarolaner started killing ﬂeas within three to four hours, and
rovided >95% control within eight hours for ﬁve weeks (Six et al.,
016). This rapid onset of efﬁcacy also means that treatment will
reak the ﬂea life cycle, as consistent control of ﬂeas in less than
4 h means that adult ﬂeas are killed before they can mature and lay
ggs (Dryden et al., 2007; Six et al., 2016). This rapid and consistent
ontrol of ﬂeas has been conﬁrmed in the ﬁeld (Cherni et al., 2016;
ecskei et al., 2016) and combined with convenient oral dosing in a
avored, chewable formulation will make sarolaner (SimparicaTM)
 valuable tool for veterinarians and pet owners in the treatment
nd control of ﬂea infestations on dogs.
. Conclusions
These ﬁve laboratory studies conﬁrmed that a single oral dose
roviding a minimum of 2 mg  sarolaner/kg provided highly effec-
ive treatment of existing C. felis infestations and persistent control
f C. felis on dogs for 35 days after treatment. Equivalent excellent
fﬁcacy was conﬁrmed against C. canis, and a known insecticide
olerant strain of C. felis.0.0* (100) 87.1 0.0* (100) 70.9 0.0* (100)
acy is given in parentheses.
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